This article is a correction to:
Neuroprotection by upregulation of the major histocompatibility complex class I (MHC I) in SOD1G93A mice
Ana Laura M. R. Tomiyama
Luciana Politti Cartarozzi
Lilian de Oliveira Coser
Gabriela Bortolança Chiarotto
Alexandre L. R. Oliveira*- Department of Structural and Functional Biology, Institute of Biology—University of Campinas (UNICAMP), Campinas, Brazil
A Corrigendum on
Neuroprotection by upregulation of the major histocompatibility complex class I (MHC I) in SOD1G93A mice
by Tomiyama, A. L. M. R., Cartarozzi, L. P., de Oliveira Coser, L., Chiarotto, G. B., and Oliveira, A. L. R. (2023). Front. Cell. Neurosci. 17:1211486. doi: 10.3389/fncel.2023.1211486
In the published article, there was an error in Figure 6 as published. The figure was published without the letters that identify each image. The corrected Figure 6 and its caption appear below.
Figure 6
Figure 6. V-GLUT-1 immunostaining in the ventral horn of the spinal cord. Double labeling counterstained with [(A), blue] DAPI, showing [(B), green] V-GLUT-1, and [(C), red] NeuN and (D) the merge, to evidence the immunostaining around the motoneurons located at the lamina IX of Rexed. Representative images of the (E) NTG, (F) vehicle, (G) 250 IU, (H) 1,000 IU, and (I) 10,000 IU. (J) Quantification of the integrated density of pixels for the V-GLUT-1 antibody, labeling excitatory inputs. The transgenic group showed a decrease in immunostaining as compared to the non-transgenic counterpart. The treatments further decreased immunostaining in a dose-dependent manner. (IFN β 250 UI: **p < 0.01; IFN β 1,000 UI: **p < 0.01, and IFN β 10,000 UI: ****p < 0.0001). Scale bar = 50 μm.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: amyotrophic lateral sclerosis, IFN β, ALS therapy, MHC-I, gliosis, neuroprotection
Citation: Tomiyama ALMR, Cartarozzi LP, de Oliveira Coser L, Chiarotto GB and Oliveira ALR (2024) Corrigendum: Neuroprotection by upregulation of the major histocompatibility complex class I (MHC I) in SOD1G93A mice. Front. Cell. Neurosci. 18:1493884. doi: 10.3389/fncel.2024.1493884
Received: 09 September 2024; Accepted: 10 September 2024;
Published: 23 September 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Tomiyama, Cartarozzi, de Oliveira Coser, Chiarotto and Oliveira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alexandre L. R. Oliveira, YWxyb2xpdiYjeDAwMDQwO3VuaWNhbXAuYnI=